Phoenix, AZNCT07901751Now EnrollingIRB Ready

Retinitis Pigmentosa (RP) Clinical Trial in Phoenix, AZ

Access cutting-edge retinitis pigmentosa (rp) treatment through this phase 2/3 clinical trial at a research site in Phoenix. Study-provided care at no cost to qualified participants.

Sponsored by Ray Therapeutics, Inc.

Quick Self-Assessment

See if you qualify for this Phoenix location

Preparing your pre-screening questions…

Expert Care in Phoenix

Access retinitis pigmentosa (rp) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related retinitis pigmentosa (rp) treatment provided free

Apply for This Phoenix Location

Check if you qualify for this retinitis pigmentosa (rp) clinical trial in Phoenix, AZ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Phoenix

    Convenient for AZ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Phoenix site if eligible
  4. 4Begin participation

About This Retinitis Pigmentosa (RP) Study in Phoenix

The purpose of this clinical trial is to evaluate the effectiveness and safety of a single injection into the eye of an investigational gene therapy in participants with retinitis pigmentosa (RP).

Sponsor: Ray Therapeutics, Inc.

Who Can Participate

Inclusion Criteria

Adults ≥18 years of age at the time of informed consent.
Able and willing to provide written informed consent prior to any study-specific procedures, in accordance with ICH GCP and applicable regulations.
Clinical diagnosis of RP, regardless of the underlying genetic mutation
Baseline best corrected distance visual acuity (BCVA) in the study eye of LogMAR 1.0 and 2.7 inclusive (approximately 20/200 - 20/9000), measured monocularly at the ETF by certified, masked personnel using grating visual acuity with conversion to logMAR equivalents.
Presence of retinal ganglion cells and/or retinal nerve fiber layer on SD-OCT testing at Screening confirmed by central image reading center.
Adequate organ function and general good health

Exclusion Criteria

Participation in another interventional clinical study (ocular or systemic) involving administration of an investigational drug, biologic, or device within 6 months prior to Screening
Planned participation in another interventional study during the course of this trial.
Prior receipt of any gene therapy (ocular or other), retinal implant, or ocular cell therapy in either eye
Presence of any pre-existing ocular condition in either eye that would preclude the planned intravitreal injection, Increase the risk of procedure-related complication, or interfere with interpretation of efficacy or safety outcomes, including hyperreflective loci/foci (HRF) on OCT imaging
Known or suspected steroid responders whose intraocular pressure could not be adequately controlled with topical pressure-lowering medications after prior use of steroid medications (ocular, periocular, or systemic).
Complicating systemic diseases; complicating systemic diseases include those in which the disease itself, or the treatment for the disease, can alter ocular and/or CNS function or confound study outcomes (e.g., prior radiation treatment of the orbit; leukemia with CNS/optic nerve involvement, uncontrolled hypertension, or similar conditions).
Known immunological response dysfunction including immuno-compromising diseases or use of immunosuppressive medications (other than physiologic corticosteroid replacement).
Positive infectious disease screen (hepatitis B, C, and/or Human Immunodeficiency Virus \[HIV\]).
Cataract or other ocular surgery (including refractive), intraocular and/or peri-ocular injection in either eye within the prior four months (i.e., 120 days) prior to screening.
Prior vitrectomy or aphakia in the study eye.
Known hypersensitivity to any component of the study treatment or contraindication to medications planned for use in the peri-procedural period (e.g., povidone-iodine to prep for intravitreal injection)
Known contraindication to prophylactic steroid regimen specified in the protocol.
Current pregnancy or breastfeeding.
Weighing less than 40 kg (88 pounds)
Any condition, including cognitive, mobility, or geographical limitations, that would prevent completion of required study visits or ETF assessments
Any condition that, in the opinion of the investigator or medical monitor, makes the participant unsuitable for the study or would interfere with the interpretation of study endpoints.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Phoenix?

Yes, this clinical trial (NCT07901751) has an active research site in Phoenix, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Retinitis Pigmentosa (RP) Treatment Options in Phoenix, AZ

If you're searching for retinitis pigmentosa (rp) treatment options in Phoenix, AZ, this clinical trial (NCT07901751) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Phoenix research site is actively enrolling participants for this phase 2/3 clinical trial. You'll receive care from experienced retinitis pigmentosa (rp) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all retinitis pigmentosa (rp) clinical trials near you to find additional studies recruiting in your area.

More Essential Tremor Trials in Phoenix, AZ

See all essential tremor clinical trials recruiting in Phoenix — not just this study.

Browse Essential Tremor Trials in Phoenix →

Browse More Trials by Condition

Essential Tremor TrialsSleep Apnea TrialsRetinitis Pigmentosa TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Phoenix?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Phoenix, AZ